What is HC Wainwright’s Forecast for VIR FY2029 Earnings?

Vir Biotechnology, Inc. (NASDAQ:VIR) – Stock analysts at HC Wainwright reduced their FY2029 earnings per share estimates for shares of Vir Biotechnology in a research report issued on Friday, January 31st. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $2.25 per share for the year, down from their prior estimate of $2.56. HC Wainwright currently has a “Buy” rating and a $110.00 target price on the stock. The consensus estimate for Vir Biotechnology’s current full-year earnings is ($3.92) per share.

Vir Biotechnology (NASDAQ:VIR) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($1.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.05) by ($0.51). The company had revenue of $2.38 million during the quarter, compared to analyst estimates of $5.54 million. Vir Biotechnology had a negative return on equity of 36.71% and a negative net margin of 678.40%. The business’s revenue for the quarter was down 9.8% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.22) earnings per share.

Other analysts have also recently issued reports about the company. Barclays dropped their price objective on Vir Biotechnology from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Monday, November 4th. JPMorgan Chase & Co. raised their target price on shares of Vir Biotechnology from $10.00 to $14.00 and gave the company a “neutral” rating in a research report on Thursday, January 9th. Leerink Partners upped their price objective on Vir Biotechnology from $18.00 to $20.00 and gave the company an “outperform” rating in a research note on Monday, January 13th. Morgan Stanley raised Vir Biotechnology from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $10.00 to $20.00 in a report on Thursday, January 9th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $19.00 target price on shares of Vir Biotechnology in a report on Wednesday, November 20th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $34.83.

Vir Biotechnology Stock Performance

Shares of NASDAQ VIR opened at $10.40 on Monday. The business has a fifty day moving average of $8.81 and a two-hundred day moving average of $8.50. Vir Biotechnology has a 52-week low of $6.56 and a 52-week high of $14.45. The stock has a market cap of $1.43 billion, a PE ratio of -2.65 and a beta of 0.51.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Vicki L. Sato sold 10,960 shares of the business’s stock in a transaction dated Wednesday, January 8th. The stock was sold at an average price of $12.52, for a total value of $137,219.20. Following the completion of the sale, the director now owns 1,312,391 shares of the company’s stock, valued at approximately $16,431,135.32. The trade was a 0.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders sold 13,383 shares of company stock valued at $160,070 in the last quarter. 15.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of VIR. Blue Trust Inc. boosted its position in shares of Vir Biotechnology by 143.5% during the third quarter. Blue Trust Inc. now owns 3,989 shares of the company’s stock valued at $30,000 after purchasing an additional 2,351 shares in the last quarter. nVerses Capital LLC purchased a new position in Vir Biotechnology in the 3rd quarter worth about $56,000. KBC Group NV boosted its stake in shares of Vir Biotechnology by 136.5% in the 4th quarter. KBC Group NV now owns 8,970 shares of the company’s stock worth $66,000 after buying an additional 5,177 shares during the last quarter. CIBC Asset Management Inc bought a new stake in Vir Biotechnology during the fourth quarter valued at approximately $74,000. Finally, Captrust Financial Advisors purchased a new stake in Vir Biotechnology in the 3rd quarter worth approximately $118,000. Institutional investors own 65.32% of the company’s stock.

Vir Biotechnology Company Profile

Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).